Vascular Dynamics said early this month it tapped former NuVasive Inc. (NSDQ:NUVA) exec and Ellipse Technologies CEO Ed Roschak as its new president and chief executive. Prior to joining Mountain View, Calif.-based Vascular Dynamics, Roschak served as prez and CEO of Ellipse Technologies, which he saw through a $410 million acquisition by NuVasive. He then took up […]
Aptus EndoSystems Inc.
Lumicell taps ex-Accuray COO Londy as CEO | Personnel Moves July 18, 2017
Lumicell said last week it tapped former Accuray (NSDQ:ARAY) chief operating officer Kelly Londy as its new chief exec, with founder W. Lee moving to take the role of prez & chief scientific officer. Prior to holding the COO position at Accuray, Londy has held leadership positions at GE Healthcare (NYSE:GE) and Royal Philips (NYSE:PHG), Lumicell said. “We are […]
Medtronic’s billion-dollar buying spree
Medtronic (NYSE:MDT) CEO Omar Ishrak has literally put his money where his mouth is since saying in early June that the world’s largest pure-play medtech maker would look for small-scale investments – $1.05 billion of that money, in fact. That’s Fridley, Minn.-based Medtronic’s announced spend on M&A since June 5, when Ishrak said the company would […]
Two a day: Medtronic acquires Aptus Endo for $110m
Medtronic (NYSE:MDT) announced its 2nd acquisition of the day this afternoon, saying it paid $110 million to acquire Aptus Endosystems and its Heli-FX device aortic securement device. Earlier today the Fridley, Minn.-based medical device giant said it picked up CardioInsight for $93 million. “We are excited to add this unique complementary, anchor technology to our aortic portfolio,” aortic […]
Aptus Endosystems CE Mark for next-generation for Heli-FX
Aptus Endosystems won CE Mark approval in the European Union for its next-generation thoracic-length delivery system for the Heli-FX device aortic securement device.
The newly green-lighted system includes a longer delivery device and additional features to treat thoracic aortic aneurysms. According to company estimates, this patient population in Europe includes 5,000 newly diagnosed patients and 12,000 patient treated overall each year.
Aptus Endosystems lands FDA nod for abdominal aneurysm device
Consumer groups urge FDA to rescind 510(k) clearance for Aptus endostapler
A group of consumer advocates demanded that the FDA heighten testing requirements for certain medical devices, taking exception to the agency’s 510(k) clearance of Aptus Endosystems Inc.’s HeliFX endostapling system.
FDA clears first stapling system to repair failed aortic grafts
Aptus Endosystems Inc. landed FDA 510(k) clearance for the first repair system designed to fix leaks and migration in implanted endografts.
An endograft is a tube used to repair a bulge in the wall of the large blood vessel that carries blood away from the heart. Aptus’ HeliFX is a minimally invasive system of staples, delivered via catheter, that allows a surgeon to reach the blood vessel and staple the top edges of the endograft to the tissue to anchor it in place.
Former Boston Scientific CEO Tobin joins Aptus Endosystems board | Personnel Moves
Former Boston Scientific Corp. (NYSE:BSX) CEO James Tobin joined the board of directors at Aptus Endosystems Inc., a device company specializing in treating abdominal aortic aneurysms.
Tobin made quite a name for himself while occupying the corner office at med-tech giant Boston Scientific, where he was chief for a decade. He officially retired in July 2009 and was succeeded by Ray Elliott.
Boston Scientific’s controversial former CEO joins the board at Aptus Endosystems
SUNNYVALE, Calif.–(BUSINESS WIRE)–Aptus Endosystems, Inc., a medical device company developing advanced technology for treating abdominal aortic aneurysms (AAA), announced today the appointment of James R. Tobin to its Board of Directors. Mr. Tobin headed Boston Scientific Corporation for 10 years and was responsible for that company’s significant growth during that period.
“The Aptus team is bringing elegant new ideas to the AAA space to address clinical needs that have to date been underserved”
